ABEVMY

Active ingredients

The drug ABEVMY contains one active pharmaceutical ingredient (API):

UNII 2S9ZZM9Q9V - BEVACIZUMAB

Bevacizumab binds to vascular endothelial growth factor (VEGF), the key driver of vasculogenesis and angiogenesis, and thereby inhibits the binding of VEGF to its receptors, Flt-1 (VEGFR-1) and KDR (VEGFR-2), on the surface of endothelial cells. Neutralising the biological activity of VEGF regresses the vascularisation of tumours, normalises remaining tumour vasculature, and inhibits the formation of new tumour vasculature, thereby inhibiting tumour growth.

Read about Bevacizumab

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code
Group title
Classification
L01FG01
Bevacizumab
L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FG VEGF/VEGFR (Vascular Endothelial Growth Factor) inhibitors
Discover more medicines within L01FG01

Authorization and marketing

This brand name is authorized in the following countries: Estonia Ireland Lithuania New Zealand Poland Tunisia South Africa

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country
Identification scheme
Identifier(s)
EE
Ravimiamet
Identifier(s): 1846841, 1846852, 1846863, 1846874, 1846885
LT
Valstybinė vaistų kontrolės tarnyba
Identifier(s): 1092483, 1092484, 1092485, 1092486, 1092487
NZ
Medicines and Medical Devices Safety Authority
Identifier(s): 21621
PL
Rejestru Produktów Leczniczych
Identifier(s): 100449085
TN
Direction de la Pharmacie et du Médicament
Identifier(s): 20343021H, 20343022H
ZA
Health Products Regulatory Authority
Identifier(s): 55/26/0256, 55/26/0257